Ji G, Yao Q, Ren M, Bai Q, Zhu X, Zhou X
Sci Rep. 2025; 15(1):7223.
PMID: 40021757
PMC: 11870997.
DOI: 10.1038/s41598-025-91640-6.
Kamali C, Tsakonas G, Hydbring P, Jatta K, Berglund A, Viktorsson K
Transl Lung Cancer Res. 2024; 13(11):2918-2933.
PMID: 39670024
PMC: 11632442.
DOI: 10.21037/tlcr-24-396.
Zhou J, Du H, Cai W
Transl Pediatr. 2024; 13(1):164-177.
PMID: 38323175
PMC: 10839273.
DOI: 10.21037/tp-23-557.
Chen N, Tyler L, Le A, Welsh E, Fang B, Elliott A
Mol Cancer Ther. 2023; 23(1):92-105.
PMID: 37748191
PMC: 10762338.
DOI: 10.1158/1535-7163.MCT-23-0218.
Chrysovergis A, Papanikolaou V, Mastronikolis N, Tsiambas E, Katsinis S, Manoli A
In Vivo. 2022; 36(3):1144-1149.
PMID: 35478149
PMC: 9087091.
DOI: 10.21873/invivo.12813.
STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.
Yanagimura N, Takeuchi S, Fukuda K, Arai S, Tanimoto A, Nishiyama A
NPJ Precis Oncol. 2022; 6(1):11.
PMID: 35228642
PMC: 8885877.
DOI: 10.1038/s41698-022-00254-y.
Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.
Dong W, Lei P, Liu X, Li Q, Cheng X
Front Immunol. 2021; 12:686057.
PMID: 34804000
PMC: 8600068.
DOI: 10.3389/fimmu.2021.686057.
Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.
Kuang Y, Xu P, Wang J, Zheng Y, Sun X, Li Z
Mol Diagn Ther. 2021; 25(4):487-494.
PMID: 34133003
PMC: 8249291.
DOI: 10.1007/s40291-021-00532-8.
RNAi technology targeting the fusion breakpoint: an opportunity for precision medicine.
Parker Kerrigan B, Ledbetter D, Kronowitz M, Phillips L, Gumin J, Hossain A
Neurooncol Adv. 2020; 2(1):vdaa132.
PMID: 33241214
PMC: 7680176.
DOI: 10.1093/noajnl/vdaa132.
Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer.
Sepesi B, Cascone T, Chun S, Altan M, Le X
Surg Oncol Clin N Am. 2020; 29(4):555-569.
PMID: 32883458
PMC: 7388816.
DOI: 10.1016/j.soc.2020.06.009.
Electrolyte Disorders Induced by Antineoplastic Drugs.
Verzicco I, Regolisti G, Quaini F, Bocchi P, Brusasco I, Ferrari M
Front Oncol. 2020; 10:779.
PMID: 32509580
PMC: 7248368.
DOI: 10.3389/fonc.2020.00779.
Drug-Induced Hypophosphatemia: Current Insights.
Megapanou E, Florentin M, Milionis H, Elisaf M, Liamis G
Drug Saf. 2019; 43(3):197-210.
PMID: 31776845
DOI: 10.1007/s40264-019-00888-1.
Synthetic lethality as an engine for cancer drug target discovery.
Huang A, Garraway L, Ashworth A, Weber B
Nat Rev Drug Discov. 2019; 19(1):23-38.
PMID: 31712683
DOI: 10.1038/s41573-019-0046-z.
Xiaoai Jiedu Recipe Inhibits Proliferation and Metastasis of Non-Small Cell Lung Cancer Cells by Blocking the P38 Mitogen-Activated Protein Kinase (MAPK) Pathway.
Wang Y, Xu C, Xu B, Li L, Li W, Wang W
Med Sci Monit. 2019; 25:7538-7546.
PMID: 31590176
PMC: 6792514.
DOI: 10.12659/MSM.917115.
IL‑21/IL‑21R inhibit tumor growth and invasion in non‑small cell lung cancer cells via suppressing Wnt/β‑catenin signaling and PD‑L1 expression.
Xue D, Yang P, Wei Q, Li X, Lin L, Lin T
Int J Mol Med. 2019; 44(5):1697-1706.
PMID: 31573051
PMC: 6777672.
DOI: 10.3892/ijmm.2019.4354.
PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer.
Remmerie M, Janssens V
Front Oncol. 2019; 9:462.
PMID: 31214504
PMC: 6558005.
DOI: 10.3389/fonc.2019.00462.
Combined EGFR/ALK Expression Analysis in Laryngeal Squamous Cell Carcinoma.
Politi A, Tsiambas E, Mastronikolis N, Peschos D, Asproudis I, Kyrodimos E
In Vivo. 2019; 33(3):815-819.
PMID: 31028202
PMC: 6559894.
DOI: 10.21873/invivo.11544.
Clinical development of targeted and immune based anti-cancer therapies.
Seebacher N, Stacy A, Porter G, Merlot A
J Exp Clin Cancer Res. 2019; 38(1):156.
PMID: 30975211
PMC: 6460662.
DOI: 10.1186/s13046-019-1094-2.
The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Guo C, Zhu Q, Tou F, Wen X, Kuang Y, Hu H
BMC Cancer. 2019; 19(1):289.
PMID: 30925904
PMC: 6441172.
DOI: 10.1186/s12885-019-5519-2.
Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway.
Chen H, Zhang Q, Zhang Y, Jia B, Zhang B, Wang C
Onco Targets Ther. 2018; 11:8201-8209.
PMID: 30568455
PMC: 6267764.
DOI: 10.2147/OTT.S173008.
